CLINICAL TRIALS PROFILE FOR BETAPACE AF
✉ Email this page to a colleague
All Clinical Trials for BETAPACE AF
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00392106 ↗ | High Intensity Focused Ultrasound (HIFU) Ablation System Study | Suspended | ProRhythm, Inc. | Phase 3 | 2006-04-01 | The purpose of this study is to determine if the HIFU Pulmonary Vein Ablation System is effective in the treatment of paroxysmal Atrial Fibrillation compared to the control of best medical therapy with FDA approved antiarrhythmic drugs. |
NCT00578617 ↗ | Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial | Completed | Abbott Medical Devices | N/A | 2006-09-01 | The CABANA pilot study is designed to test the hypothesis that the treatment strategy of percutaneous left atrial catheter ablation for the purpose of the elimination of atrial fibrillation (AF) is superior to current state-of-the-art therapy with either rate control or anti-arrhythmic drugs for reducing AF recurrences at 1 year follow-up. |
NCT00578617 ↗ | Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial | Completed | Duke Clinical Research Institute | N/A | 2006-09-01 | The CABANA pilot study is designed to test the hypothesis that the treatment strategy of percutaneous left atrial catheter ablation for the purpose of the elimination of atrial fibrillation (AF) is superior to current state-of-the-art therapy with either rate control or anti-arrhythmic drugs for reducing AF recurrences at 1 year follow-up. |
NCT00578617 ↗ | Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial | Completed | St. Jude Medical | N/A | 2006-09-01 | The CABANA pilot study is designed to test the hypothesis that the treatment strategy of percutaneous left atrial catheter ablation for the purpose of the elimination of atrial fibrillation (AF) is superior to current state-of-the-art therapy with either rate control or anti-arrhythmic drugs for reducing AF recurrences at 1 year follow-up. |
NCT00578617 ↗ | Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial | Completed | Mayo Clinic | N/A | 2006-09-01 | The CABANA pilot study is designed to test the hypothesis that the treatment strategy of percutaneous left atrial catheter ablation for the purpose of the elimination of atrial fibrillation (AF) is superior to current state-of-the-art therapy with either rate control or anti-arrhythmic drugs for reducing AF recurrences at 1 year follow-up. |
NCT00589303 ↗ | AV Node Ablation and Pacemaker Therapy Compared to Drug Therapy for Atrial Fibrillation - Pilot Study | Terminated | Medtronic | Phase 3 | 2007-12-01 | The purpose of this study is to determine whether early atrioventricular node (AVN) ablation with pacing device therapy will reduce death and hospitalization when compared to the conventional drug therapy in elderly patients with recurrent and symptomatic atrial fibrillation (AF). |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for BETAPACE AF
Condition Name
Clinical Trial Locations for BETAPACE AF
Trials by Country
Clinical Trial Progress for BETAPACE AF
Clinical Trial Phase
Clinical Trial Sponsors for BETAPACE AF
Sponsor Name